Cargando…

Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms

SIMPLE SUMMARY: Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid neoplasms characterized, at the time of their presentation, by the simultaneous presence of both myelodysplastic and myeloproliferative features. In MDS/MPN, the karyotype is often normal but mutations in genes...

Descripción completa

Detalles Bibliográficos
Autores principales: Palomo, Laura, Acha, Pamela, Solé, Francesc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124412/
https://www.ncbi.nlm.nih.gov/pubmed/33925681
http://dx.doi.org/10.3390/cancers13092120
_version_ 1783693198133035008
author Palomo, Laura
Acha, Pamela
Solé, Francesc
author_facet Palomo, Laura
Acha, Pamela
Solé, Francesc
author_sort Palomo, Laura
collection PubMed
description SIMPLE SUMMARY: Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid neoplasms characterized, at the time of their presentation, by the simultaneous presence of both myelodysplastic and myeloproliferative features. In MDS/MPN, the karyotype is often normal but mutations in genes that are common across myeloid neoplasms can be detected in a high proportion of cases by targeted sequencing. In this review, we intend to summarize the main genetic findings across all MDS/MPN overlap syndromes and discuss their relevance in the management of patients. ABSTRACT: Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are myeloid neoplasms characterized by the presentation of overlapping features from both myelodysplastic syndromes and myeloproliferative neoplasms. Although the classification of MDS/MPN relies largely on clinical features and peripheral blood and bone marrow morphology, studies have demonstrated that a large proportion of patients (~90%) with this disease harbor somatic mutations in a group of genes that are common across myeloid neoplasms. These mutations play a role in the clinical heterogeneity of these diseases and their clinical evolution. Nevertheless, none of them is specific to MDS/MPN and current diagnostic criteria do not include molecular data. Even when such alterations can be helpful for differential diagnosis, they should not be used alone as proof of neoplasia because some of these mutations may also occur in healthy older people. Here, we intend to review the main genetic findings across all MDS/MPN overlap syndromes and discuss their relevance in the management of the patients.
format Online
Article
Text
id pubmed-8124412
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81244122021-05-17 Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms Palomo, Laura Acha, Pamela Solé, Francesc Cancers (Basel) Review SIMPLE SUMMARY: Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid neoplasms characterized, at the time of their presentation, by the simultaneous presence of both myelodysplastic and myeloproliferative features. In MDS/MPN, the karyotype is often normal but mutations in genes that are common across myeloid neoplasms can be detected in a high proportion of cases by targeted sequencing. In this review, we intend to summarize the main genetic findings across all MDS/MPN overlap syndromes and discuss their relevance in the management of patients. ABSTRACT: Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are myeloid neoplasms characterized by the presentation of overlapping features from both myelodysplastic syndromes and myeloproliferative neoplasms. Although the classification of MDS/MPN relies largely on clinical features and peripheral blood and bone marrow morphology, studies have demonstrated that a large proportion of patients (~90%) with this disease harbor somatic mutations in a group of genes that are common across myeloid neoplasms. These mutations play a role in the clinical heterogeneity of these diseases and their clinical evolution. Nevertheless, none of them is specific to MDS/MPN and current diagnostic criteria do not include molecular data. Even when such alterations can be helpful for differential diagnosis, they should not be used alone as proof of neoplasia because some of these mutations may also occur in healthy older people. Here, we intend to review the main genetic findings across all MDS/MPN overlap syndromes and discuss their relevance in the management of the patients. MDPI 2021-04-27 /pmc/articles/PMC8124412/ /pubmed/33925681 http://dx.doi.org/10.3390/cancers13092120 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Palomo, Laura
Acha, Pamela
Solé, Francesc
Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
title Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
title_full Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
title_fullStr Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
title_full_unstemmed Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
title_short Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
title_sort genetic aspects of myelodysplastic/myeloproliferative neoplasms
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124412/
https://www.ncbi.nlm.nih.gov/pubmed/33925681
http://dx.doi.org/10.3390/cancers13092120
work_keys_str_mv AT palomolaura geneticaspectsofmyelodysplasticmyeloproliferativeneoplasms
AT achapamela geneticaspectsofmyelodysplasticmyeloproliferativeneoplasms
AT solefrancesc geneticaspectsofmyelodysplasticmyeloproliferativeneoplasms